Management of Abnormal Liver Function Tests with Enfortumab Vedotin
When liver function tests become abnormal during enfortumab vedotin therapy, immediately repeat testing within 2-5 days and apply a tiered management algorithm based on ALT/AST elevation magnitude and bilirubin levels, with drug interruption required for ALT/AST >3× baseline (or >5× ULN from normal baseline) and permanent discontinuation for ALT/AST >20× ULN. 1
Initial Assessment and Monitoring
Enfortumab vedotin commonly causes changes in liver function tests, listed as one of the most frequent side effects in both monotherapy and combination therapy with pembrolizumab 2. When LFT abnormalities are detected:
- Measure comprehensive liver panel: ALT, AST, alkaline phosphatase (ALP), GGT, total bilirubin (TBIL), direct bilirubin (DBL), CK, and INR 1
- Assess bilirubin fractionation: Direct bilirubin helps distinguish true hepatocellular injury from Gilbert's syndrome or hemolysis 1
- Note the pattern: Research shows AST levels significantly increase with enfortumab vedotin treatment, while ALT elevations may be less pronounced 3
Algorithmic Management Based on Severity
For ALT/AST Elevations from Normal Baseline:
3-5× ULN (or 3-5× baseline if elevated at start):
- Repeat blood tests within 2-5 days 1
- Continue treatment if bilirubin remains normal or at baseline 1
- If bilirubin is >2× baseline or >2× ULN: Withhold drug and repeat tests within 2-3 days 1
5-20× ULN (or 5-20× baseline):
- Interrupt or reduce study drug dose 1
- If bilirubin >2× baseline: Consider permanent discontinuation unless alternative explanation identified 1
- Initiate close monitoring 2-3 times weekly, adjusting frequency based on clinical scenario 1
>20× ULN (or >20× baseline):
- Permanent discontinuation regardless of bilirubin level 1
Critical Bilirubin Considerations:
For patients with Gilbert's syndrome, use direct bilirubin >2× baseline as the trigger for action rather than total bilirubin 1. This is essential because total bilirubin fluctuates significantly in these patients and may lead to inappropriate treatment interruptions.
Excluding Alternative Causes
Before attributing LFT abnormalities solely to enfortumab vedotin, systematically exclude:
- Malignancy progression: Liver metastases are the most common cause of LFT elevations in oncology patients 1
- Biliary obstruction: Particularly relevant given the cholestatic pattern some patients develop
- Concomitant medications: Review all prescribed, over-the-counter, herbal, and dietary supplements 1
- Viral hepatitis: Test for hepatitis A, B, and C if not previously done 4
- Imaging: Obtain abdominal imaging to assess for metastatic disease, biliary dilatation, or other structural abnormalities 1
The timing of LFT elevations relative to drug initiation, the pattern of injury (hepatocellular vs. cholestatic), and degree of elevation provide important diagnostic clues 1.
Monitoring Frequency and Duration
Initial monitoring schedule:
- 2-3 times weekly when drug is withheld for significant elevations 1
- Continue monitoring until resolution or stabilization, regardless of whether drug is discontinued 1
- Observe for clinical features of hepatic decompensation: ascites, encephalopathy, coagulopathy 1
Rechallenge Considerations
Rechallenge with the same or lower dose may be considered based on benefit-risk assessment if:
- No alternative explanation was found and LFTs normalized 1
- The patient had significant clinical benefit before toxicity
- Close monitoring can be maintained
However, if ALT elevations recur on rechallenge, permanent discontinuation should be strongly considered 1.
Special Populations
Elderly patients (≥75 years): Safety profiles appear similar to younger patients, with no significant difference in adverse event rates 3. However, these patients may have reduced physiologic reserve.
Poor performance status (PS≥2): While LFT abnormalities occur at similar rates, these patients have significantly worse progression-free survival and lower albumin levels, which independently predicts mortality 3. Lower albumin may affect drug pharmacokinetics and toxicity.
Common Pitfalls to Avoid
- Don't ignore early AST elevations: AST rises significantly with enfortumab vedotin and may precede ALT changes 3
- Don't assume all LFT elevations are drug-related: In oncology patients, disease progression is the most common cause 1
- Don't use total bilirubin alone in Gilbert's syndrome: This leads to unnecessary treatment interruptions 1
- Don't delay repeat testing: The 2-5 day window for reassessment is critical for catching rapidly progressive injury 1
Clinical Context
The FDA label confirms that liver function test changes are among the most common side effects with enfortumab vedotin 2. While dose reductions for toxicity may actually improve progression-free survival without compromising efficacy 5, the decision to reduce versus discontinue must be individualized based on the severity algorithm above and exclusion of alternative causes.